Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?].

Turpin A, Mailliez A, Vennin P, Bonneterre J.

Gynecol Obstet Fertil. 2014 May;42(5):325-30. doi: 10.1016/j.gyobfe.2013.11.006. French.

PMID:
24411340
2.

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.

Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast Cancer Res Treat. 2012 Jan;131(1):117-26. doi: 10.1007/s10549-011-1767-9.

PMID:
21935602
3.
4.

Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.

Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, Evison F, Dasgupta P, O'Brien T, Khan MS.

BJU Int. 2014 Sep;114(3):389-95. doi: 10.1111/bju.12608.

6.

Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.

Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Boy C, Forsting M, Bockisch A, Antoch G, Stahl A.

Acta Radiol. 2011 Nov 1;52(9):1009-14. doi: 10.1258/ar.2011.100507.

PMID:
21969709
7.

Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.

Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, Weber WA, Ulaner GA.

J Nucl Med. 2014 Oct;55(10):1578-83. doi: 10.2967/jnumed.114.143297.

8.

Performance of FDG PET/CT in the clinical management of breast cancer.

Groheux D, Espié M, Giacchetti S, Hindié E.

Radiology. 2013 Feb;266(2):388-405. doi: 10.1148/radiol.12110853. Review.

PMID:
23220901
9.

The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients.

Sen F, Akpinar AT, Ogur U, Duman G, Tamgac F, Alper E.

Nucl Med Commun. 2013 Jun;34(6):571-6. doi: 10.1097/MNM.0b013e328360d8ec.

PMID:
23549550
10.

Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.

Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT.

Oncologist. 2011;16(6):772-82. doi: 10.1634/theoncologist.2010-0378.

11.

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.

Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP.

Cancer. 2009 Nov 1;115(21):5038-47. doi: 10.1002/cncr.24534.

12.

Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.

Lee JW, Lee SM, Lee HS, Kim YH, Bae WK.

Ann Nucl Med. 2012 Oct;26(8):627-33. doi: 10.1007/s12149-012-0622-3.

PMID:
22729551
13.

Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G, Heusner TA.

Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63. doi: 10.1007/s00259-012-2077-0.

PMID:
22392069
14.

CT staging for breast cancer patients with poor prognostic tumours.

James JJ, McMahon MA, Tennant SL, Cornford EJ.

Breast. 2012 Dec;21(6):735-8. doi: 10.1016/j.breast.2012.08.001.

PMID:
22959310
15.

Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.

Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT.

Gynecol Oncol. 2010 Mar;116(3):389-94. doi: 10.1016/j.ygyno.2009.10.059.

PMID:
19926121
16.

Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.

Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, Fontanillas M, Pons F.

J Clin Oncol. 2008 Oct 10;26(29):4746-51. doi: 10.1200/JCO.2008.17.1496.

PMID:
18695254
17.
18.

(18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?

Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J, Wasgindt S, Suetterlin M, Schoenberg SO, Sutton EJ, Wasser K.

Eur Radiol. 2015 Aug;25(8):2460-9. doi: 10.1007/s00330-015-3630-6.

PMID:
25680729
19.

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.

Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G, Stahl A.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1077-86. doi: 10.1007/s00259-010-1399-z.

PMID:
20204355
20.

The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.

Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M.

Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Review.

Items per page

Supplemental Content

Support Center